VELPHORO TABLET (CHEWABLE)

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

IRON (SUCROFERRIC OXYHYDROXIDE)

Disponibbli minn:

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD

Kodiċi ATC:

V03AE05

INN (Isem Internazzjonali):

SUCROFERRIC OXYHYDROXIDE

Dożaġġ:

500MG

Għamla farmaċewtika:

TABLET (CHEWABLE)

Kompożizzjoni:

IRON (SUCROFERRIC OXYHYDROXIDE) 500MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/90

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

PHOSPHATE-REMOVING AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0108536040; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2018-01-05

Karatteristiċi tal-prodott

_ _
_Page 1 of 29_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
VELPHORO
®
Sucroferric Oxyhydroxide Chewable Tablet
500 mg iron (equivalent to 2500 mg sucroferric oxyhydroxide)
Phosphate Binder
Manufactured by:
Vifor Fresenius Medical Care Renal Pharma Ltd.
Rechenstrasse 37, 9014 St. Gallen
Switzerland
Imported by:
Otsuka Canada Pharmaceutical Inc.
Saint-Laurent, Quebec, H4S 2C9
Date of Initial Approval:
January 5, 2018
Date of Revision:
August 30, 2021
Submission Control No: 244717
_ _
_ _
_Page 2 of 29_
TABLE OF CONTENTS
TABLE OF
CONTENTS.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 4
1
INDICATIONS
...........................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................
4
3
DOSAGE AND ADMINISTRATION
.........................................................................
4
3.1
Dosing
Considerations.....................................................................................
4
3.2
Recommended Dose and Dosage Adjustment
.............................................. 4
3.3
Administration...................................................................................................
5
3.4
Missed
Dose.....................................................................................................
5
4
OVERDOSAGE
.........................................................................................................
5
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 5
6
WARNINGS AND
PRECAUTIONS.............................